CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Report for D007248: Infertility, Male NIH

(Synonyms: Infertility, Male)

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)


Name (Synonyms) Correlation
drug1054 Exposure: Covid-19 infection Wiki 1.00

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D007246 Infertility NIH 0.38

Correlated HPO Terms (2)


Name (Synonyms) Correlation
HP:0003251 Male infertility HPO 1.00
HP:0000789 Infertility HPO 0.38

There is one clinical trial.

Clinical Trials


1 Determining the Reproductive Health of Men Post-COVID-19 Infection

Study rationale 1. An increasing proportion of the worldwide population is being infected with COVID-19. 2. There are ongoing and currently unanswered safety concerns about the effects of COVID-19 on reproductive health. 3. It will be immensely reassuring to rapidly report that COVID-19 has no detectable effects on male endocrine or sperm function. Conversely, if COVID-19 does impair male reproductive health, appropriate screening can be performed in couples trying to conceive, and further research can be undertaken. 4. The proposed study will be simple, rapid, and authoritative for the UK and worldwide.

NCT04414904 Infertility, Male Testosterone Deficiency Other: Exposure: Covid-19 infection
MeSH:Infertility Infertility, Male
HPO:Infertility Male infertility

Primary Outcomes

Description: Sperm concentration (x10^6/ml) between case and control group.

Measure: Semen parameters

Time: 3 visits (up to 75 days apart)

Description: Sperm Motility (%) between case and control group.

Measure: Sperm Parameters

Time: 3 visits (up to 75 days apart)

Description: Sperm normal morphology (%) between case and control group.

Measure: Sperm Parameters

Time: 3 visits (up to 75 days apart)

Description: Testosterone (nmol/L) between case and control group.

Measure: Hormones measurement

Time: 3 visits (up to 75 days apart)

Description: Follicle Stimulating Hormone(IU/L) between case and control group.

Measure: Hormones measurement

Time: 3 visits (up to 75 days apart)

Description: Luteinising hormone(IU/L) between case and control group.

Measure: Hormones measurement

Time: 3 visits (up to 75 days apart)

Secondary Outcomes

Description: Compare seminal reactive oxidative species (RLU/second/10^6sperm) between case and control group.

Measure: Seminal Reactive oxygen species

Time: 3 visits (up to 75 days apart)

Description: Compare Sperm DNA fragmentation rate (%) between case and control group.

Measure: Sperm DNA fragmentation rate

Time: 3 visits (up to 75 days apart)


HPO Nodes